Clinical Trial Update: Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20 [Phase 1]

View source ↗

Summary

Phase 1 PK/PD and safety study evaluating subcutaneously administered insulin analogs (Humalog) and Humulin-R with and without recombinant hyaluronidase (rHuPH2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Humalog (insulin lispro)
• Humulin R
• Recombinant human hyaluronidase (rHuPH20) (recombinant human hyaluronidase)

Snippet

Sponsor: Halozyme Therapeutics | Conditions: Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2014-07-14